1-Year Safety of 3-Month Dual Antiplatelet Therapy Followed by Aspirin or P2Y<sub>12</sub> Receptor Inhibitor Monotherapy Using a Bioabsorbable Polymer Sirolimus-Eluting Stent-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

1-Year Safety of 3-Month Dual Antiplatelet Therapy Followed by Aspirin or P2Y₁₂ Receptor Inhibitor Monotherapy Using a Bioabsorbable Polymer Sirolimus-Eluting Stent

Published:2020-12-25 Issue:1 Volume:85 Page:19-26
ISSN:1346-9843
Container-title:Circulation Journal
language:en
Short-container-title:Circ J

Author:

Kozuma Ken¹,Kinoshita Yoshihisa²,Hioki Hirofumi¹,Nanasato Mamoru³,Ito Yoshiaki⁴,Yamaguchi Junichi⁵,Shiode Nobuo⁶,Hibi Kiyoshi⁷,Tanabe Kengo⁸,Ako Junya⁹,Morino Yoshihiro¹⁰,Hirohata Atsushi¹¹,Sonoda Shinjo¹²,Nakagawa Yoshihisa¹³,Ikari Yuji¹⁴,

Affiliation:

1. Department of Cardiology, Teikyo University

2. Department of Cardiology, Toyohashi Heart Center

3. Department of Cardiology, Sakakibara Heart Institute

4. Department of Cardiology, Saiseikai Yokohamashi Tobu Hospital

5. Department of Cardiology, Tokyo Women’s Medical University

6. Department of Cardiology, Hiroshima City Hiroshima Citizens Hospital

7. Division of Cardiology, Yokohama City University Medical Center

8. Division of Cardiology, Mitsui Memorial Hospital

9. Department of Cardiology, Kitazato University Hospital

10. Department of Cardiology, Iwate Medical University

11. Department of Cardiology, The Sakakibara Heart Institute of Okayama

12. Department of Cardiology, Hospital of the University of Occupational and Environmental Health

13. Department of Cardiology, Shiga University of Medical Science Hospital

14. Department of Cardiology, Tokai University Hospital

Publisher

Japanese Circulation Society

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Link

https://www.jstage.jst.go.jp/article/circj/85/1/85_CJ-20-0644/_pdf

Reference27 articles.

1. 1. Palmerini T, Biondi-Zoccai G, Della Riva D, Stettler C, Sangiorgi D, D’Ascenzo F, et al. Stent thrombosis with drug-eluting and bare-metal stents: Evidence from a comprehensive network meta-analysis. Lancet 2012; 379: 1393–1402.

2. 2. Otsuka F, Vorpahl M, Nakano M, Foerst J, Newell JB, Sakakura K, et al. Pathology of second-generation everolimus-eluting stents versus first-generation sirolimus- and paclitaxel-eluting stents in humans. Circulation 2014; 129: 211–223.

3. 3. Natsuaki M, Morimoto T, Yamamoto E, Shiomi H, Furukawa Y, Abe M, et al. One-year outcome of a prospective trial stopping dual antiplatelet therapy at 3 months after everolimus-eluting cobalt-chromium stent implantation: ShortT and OPtimal duration of Dual AntiPlatelet Therapy after everolimus-eluting cobalt-chromium stent (STOPDAPT) trial. Cardiovasc Interv Ther 2016; 31: 196–209.

4. 4. Valgimigli M, Campo G, Monti M, Vranckx P, Percoco G, Tumscitz C, et al. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: A randomized multicenter trial. Circulation 2012; 125: 2015–2026.

5. 5. Kim BK, Hong MK, Shin DH, Nam CM, Kim JS, Ko YG, et al. A new strategy for discontinuation of dual antiplatelet therapy: The RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). Am J Coll Cardiol 2012; 60: 1340–1348.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. One-Month Dual Antiplatelet Therapy Followed by P2Y<sub>12</sub> Inhibitor Monotherapy After Biodegradable Polymer Drug-Eluting Stent Implantation　― The REIWA Region-Wide Registry ―;Circulation Journal;2024-05-24

2. Asian perspective on the recently published practice guideline for acute coronary syndrome by ESC;European Heart Journal: Acute Cardiovascular Care;2023-10-13

3. Bleeding Complications in Patients Undergoing Percutaneous Coronary Intervention;Reviews in Cardiovascular Medicine;2022-08-15

4. Bleeding avoidance strategies in percutaneous coronary intervention;Nature Reviews Cardiology;2021-08-23

5. Ischemic/bleeding event after short dual-antiplatelet therapy in patients with high bleeding risk: Sub-analysis of the MODEL U-SES study;Journal of Cardiology;2021-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3